Press Releases

Date Title and Summary Additional Formats
Toggle Summary Evoke Pharma Reports First Quarter 2015 Results
Company Begins Preparation for Commercialization of EVK-001
View HTML
Toggle Summary Evoke Pharma Schedules Webcast and Conference Call for First Quarter 2015 Financial Results
SOLANA BEACH, Calif., April 30, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the first quarter of 2015 on Thursday, May 14, 2015,
View HTML
Toggle Summary Evoke Pharma Achieves Significant Manufacturing Milestone With Successful Completion of Commercial Scale Production of EVK-001
Manufacturing Program Includes Three Year Registration Stability Data
View HTML
Toggle Summary Evoke Pharma Granted European Union Formulation Patent for EVK-001
SOLANA BEACH, Calif., April 9, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the European Patent Office has granted the Company European Union (EU) patent no.
View HTML
Toggle Summary Evoke Pharma to Present at the 27th Annual ROTH Conference
SOLANA BEACH, Calif. , March 4, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, will host an investor presentation on Wednesday, March 11, 2015 at 10:00AM PT at the 27 th Annual ROTH Conference .
View HTML
Toggle Summary Evoke Pharma Reports Fourth Quarter and Year End 2014 Results
SOLANA BEACH, Calif., March 4, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the fourth quarter and year ended December 31, 2014.
View HTML
Toggle Summary Evoke Pharma Schedules Webcast and Conference Call for Fourth Quarter 2014 Financial Results
SOLANA BEACH, Calif. , Feb. 19, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the fourth quarter of 2014 on Wednesday, March 4, 2015
View HTML
Toggle Summary Evoke Pharma Outlines Progress on Clinical Program
SOLANA BEACH, Calif. , Feb. 2, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today provided an update on its clinical program for EVK-001, its novel metoclopramide nasal spray for the relief of
View HTML
Toggle Summary Evoke Pharma's EVK-001 Showed No QT Prolongation in Thorough ECG (TQT) Study
SOLANA BEACH, Calif. , Dec. 2, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced results from an electrocardiogram (ECG) study that assessed the potential of metoclopramide nasal
View HTML
Toggle Summary Evoke Pharma to Present at LD Micro Conference
SOLANA BEACH, Calif. , Nov. 25, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, will host an investor presentation on Thursday, December 4, 2014 at 11:30AM PT at the LD Micro Main Event VII
View HTML